Hull to Stay with Combined Hologic, Gen-Probe; Integration Planning Proceeding | GenomeWeb

NEW YORK (GenomeWeb News) – Hologic provided an update on its pending $3.7 billion acquisition of Gen-Probe after the close of the market on Wednesday, saying the deal is expected to be completed on or about Aug. 1.

In addition, its said that Carl Hull, chairman and CEO of Gen-Probe, has agreed to stay on at Hologic for at least 15 months to help direct the combined company's diagnostics business.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: role for epigenetic in neuronal excitability, and more.

The new Office of Research Integrity director is grappling with complaints from her staff, according to ScienceInsider.

Italian researchers link SNPs in the PDSS2 gene to coffee consumption in a new paper.

A gene-editing ban has been interpreted to include mitochondrial transfer, Technology Review reports.